XML 64 R28.htm IDEA: XBRL DOCUMENT
v3.20.1

Revenues (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2020
Revenue from Contract with Customer [Abstract] |
Revenues by product | Revenues by product are summarized as follows:
|  | For the Three Months Ended March 31,
(In millions) |  | 2020 |  | 2019
|  | United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis (MS): |  |  |  |  |  |  |  |  |  |  |  |
Fumarate* |  | $ | 777.5 |  |  | $ | 323.3 |  |  | $ | 1,100.8 |  |  | $ | 717.7 |  |  | $ | 281.1 |  |  | $ | 998.8 |
Interferon** |  | 292.6 |  |  | 173.4 |  |  | 466.0 |  |  | 327.3 |  |  | 173.6 |  |  | 500.9 |
TYSABRI |  | 277.7 |  |  | 244.7 |  |  | 522.4 |  |  | 245.0 |  |  | 215.4 |  |  | 460.4 |
FAMPYRA |  | — |  |  | 28.3 |  |  | 28.3 |  |  | — |  |  | 22.9 |  |  | 22.9 |
Subtotal: MS product revenues |  | 1,347.8 |  |  | 769.7 |  |  | 2,117.5 |  |  | 1,290.0 |  |  | 693.0 |  |  | 1,983.0 |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |  |
SPINRAZA |  | 235.4 |  |  | 329.6 |  |  | 565.0 |  |  | 223.3 |  |  | 295.2 |  |  | 518.5 |
Biosimilars: |  |  |  |  |  |  |  |  |  |  |  |
BENEPALI |  | — |  |  | 133.5 |  |  | 133.5 |  |  | — |  |  | 124.0 |  |  | 124.0 |
IMRALDI |  | — |  |  | 61.6 |  |  | 61.6 |  |  | — |  |  | 35.7 |  |  | 35.7 |
FLIXABI |  | — |  |  | 23.7 |  |  | 23.7 |  |  | — |  |  | 14.7 |  |  | 14.7 |
Subtotal: Biosimilar product revenues |  | — |  |  | 218.8 |  |  | 218.8 |  |  | — |  |  | 174.4 |  |  | 174.4 |
Other: |  |  |  |  |  |  |  |  |  |  |  |
FUMADERM |  | — |  |  | 3.3 |  |  | 3.3 |  |  | — |  |  | 4.1 |  |  | 4.1 |
Total product revenues |  | $ | 1,583.2 |  |  | $ | 1,321.4 |  |  | $ | 2,904.6 |  |  | $ | 1,513.3 |  |  | $ | 1,166.7 |  |  | $ | 2,680.0 |
*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became available in the U.S. in November 2019. **Interferon includes AVONEX and PLEGRIDY.
Analysis of change In reserves | An analysis of the change in reserves for discounts and allowances is summarized as follows:
(In millions) |  | Discounts |  | Contractual Adjustments |  | Returns |  | Total
Balance, as of December 31, 2019 |  | $ | 131.1 |  |  | $ | 1,027.3 |  |  | $ | 40.5 |  |  | $ | 1,198.9 |
Current provisions relating to sales in current year |  | 200.7 |  |  | 827.9 |  |  | 4.7 |  |  | 1,033.3 |
Adjustments relating to prior years |  | (0.5 | ) |  | (15.9 | ) |  | (0.5 | ) |  | (16.9 | )
Payments/credits relating to sales in current year |  | (73.4 | ) |  | (310.3 | ) |  | — |  |  | (383.7 | )
Payments/credits relating to sales in prior years |  | (112.2 | ) |  | (432.8 | ) |  | (4.8 | ) |  | (549.8 | )
Balance, as of March 31, 2020 |  | $ | 145.7 |  |  | $ | 1,096.2 |  |  | $ | 39.9 |  |  | $ | 1,281.8 |
Total reserves included in consolidated balance sheets | The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:
(In millions) |  | As of March 31, 2020 |  | As of December 31, 2019
Reduction of accounts receivable, net |  | $ | 235.4 |  |  | $ | 197.8 |
Component of accrued expenses and other |  | 1,046.4 |  |  | 1,001.1 |
Total revenue-related reserves |  | $ | 1,281.8 |  |  | $ | 1,198.9 |
Revenues from anti-CD20 therapeutic programs | Revenues from anti-CD20 therapeutic programs are summarized below. For the purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
|  | For the Three Months Ended March 31,
(In millions) |  | 2020 |  | 2019
Biogen’s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA |  | $ | 341.3 |  |  | $ | 390.8 |
Other revenues from anti-CD20 therapeutic programs |  | 179.1 |  |  | 126.6 |
Total revenues from anti-CD20 therapeutic programs |  | $ | 520.4 |  |  | $ | 517.4 |
Other revenues | Other revenues are summarized as follows:
|  | For the Three Months Ended March 31,
(In millions) |  | 2020 |  | 2019
Revenues from collaborative and other relationships: |  |  |  |
Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis |  | $ | 3.7 |  |  | $ | 24.8 |
Profit (loss) earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc. |  | 0.2 |  |  | (0.4 | )
Other royalty and corporate revenues: |  |  |  |
Royalty |  | 11.4 |  |  | 3.9 |
Other corporate |  | 94.0 |  |  | 264.1 |
Total other revenues |  | $ | 109.3 |  |  | $ | 292.4 |

X
- Definition Analysis of amount of and change in product revenue reserves. + References No definition available. + Details
Name: | biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Other revenues [Table Text Block] + References No definition available. + Details
Name: | biib_OtherrevenuesTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenues from anti-CD20 therapeutic programs + References No definition available. + Details
Name: | biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of total product revenue reserves included in consolidated balance sheets. + References No definition available. + Details
Name: | biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration